post in Medical Technology

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

... endpoint of elimination of ocular pain one day post surgery. When considered ... experiencing no pain was assessed at Day 1 post surgery, and the proportion of patients with ... of ocular inflammation was assessed on Day 15 post surgery. Ocular inflammation was evaluated using ...

University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

... value of monitoring cell- mediated immunity (CMI) post transplant in recipients of kidney transplants ... with Cylex ImmuKnow(R) in the management of post kidney transplant recipients," will be presented ... controls but significantly higher (p levels post transplant (see below). -- Blood samples taken ...

BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting

... which are ongoing at between four and 27 months post first injection. The sixth complete response ... response, five of which are ongoing 7-13 months post first injection and two of which have no disease ... prolonged periods of stable disease as well as post treatment responses after being withdrawn from ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

... SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing time to symptom resolution ... Convention Center -- Sails Pavilion, #T1140 A post hoc analysis of the Kamm study (study 302) ... mild to moderate UC were analyzed as part of this post hoc analysis of an 8-week study. Patients in the ...

RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION

... Findings of pre- and post study at Rice Memorial Hospital translates into ... at Rice Memorial Hospital was collected pre- and post SinglePointe implementation to look at ... that missing medications were less of a problem post SinglePointe implementation. "It is gratifying ...

New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study

... greater volumes of fat to be transferred, and its post operative use to stabilize the graft ensuring its ... types of participants: post lumpectomy patients, post mastectomy patients or those post breast biopsy, that were left with a filling ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... off and perhaps even go down a bit in people age 90 and above. post Traumatic Stress Disorder May Raise Alzheimer's Risk; Moderate Alcohol May Lower It Two studies from ICAD 2009 looked at how post traumatic stress disorder (PTSD) and alcohol consumption may affect risk ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

... the FDA mandated that the catheters' manufacturer must conduct two post approval studies (PAS) to collect long term safety data. The mandated ... and not to devices used off-label in clinical practice. The first PAS is a post approval registry, which will collect safety (adverse event) data and ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization in the pivotal Phase 3 trial, 18 patients (29%) in the ... 0.02). Additionally, the GVHD treatment response at Day 40 (10 days post cessation of therapy) was 16 of 31 (52%) vs. 5 of 29 (17%) in the orBec(R) ...

ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services

... multiple antipsychotic medications with appropriate justification post discharge continuing care plan created post discharge continuing care plan transmitted to next level of care provider ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... significant improvements in measures of nerve health at 180 days post treatment. -- Initiation of repeat dosing Phase 2 clinical trials ... between placebo and treated subjects at primary evaluation point 180 days post treatment. Analysis of these data is ongoing. Business -- ...

Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207

... vitro interactions investigated included synergy studies, rate of killing, post antibiotic effect and intracellular activity against MTB in macrophages. ... the various MTB strains and showed increased rate of killing, enhanced post antibiotic effect and intracellular killing activity. Results showed that ...

PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop

... data provide the first tangible evidence of the predicted mechanisms of post poisoning intervention with rBChE. "The majority of our research to date ... spores and blood samples were collected every 4-8 hours beginning 24-hours post exposure to assess anthrax bacteremia and protective antigen in blood. ...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

... a side effect of particular concern in the osteoarthritis population. A post hoc pooled analysis of the blood pressure data from the 301 and 302 ... not a pre-specified secondary endpoint of the study, a post hoc analysis showed that naproxcinod 375 mg bid was also ...

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

... the study and the statistical analysis announced today was conducted on a post hoc basis. Pascal Pfister MD, Chief Scientific Officer and Head of ... data from our most advanced CINOD at EULAR. We believe the results of the post hoc statistical analysis on blood pressure are particularly encouraging, ...

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

... p=0.02). The mean improvement in sensory (sural) NCV measurements 180 days post treatment was 1.2 Meters/sec with SB-509 treatment compared to -0.4 ... sum of improvement of all lower extremity motor NCV measurements 180 days post treatment was 0.8 Meters/sec with SB-509 treatment compared to -0.9 ...

Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer

... has been designed to establish the efficacy and safety of PI-88 in the post resection liver cancer setting. The trial will recruit approximately 600 ... of cancer. In April 2007, data from a randomised phase 2 trial in the post resection liver cancer setting was presented at the European Association ...

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

... "FEC75 +H"), and cyclophosphamide 500 mg/m2 all IV every 21 D x 4 cycles. post ASCO '05, HER2+ pts received H (4 mg/kg on Day 1, then 2 mg/kg wkly x 12 ... Breast/Ax All patients with surgery post CT 179 34 (27-41) ER or PR+ ...

Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary

... (p=0.92) P value = vs. placebo * Primary endpoint analysis was 30 day post last dose, Day 59, in cohorts treated for 5 weeks and 14 days post last dose, Day 99, in the cohort treated for 13 weeks ** Per ...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

... d'Urologie in Paris. In addition, one of three analyses presented -- a post hoc analysis -- showed that AVODART provides a pattern of increasing ... with moderate-to-severe symptoms of BPH and prostate enlargement" This post hoc analysis of the CombAT two-year data is a comparison of efficacy for ...

Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc

... the Reviroc-treated patient group had an 80% chance of survival at 3 years post transplantation, while the CIBMTR control group had a 55% chance of survival at 3 years post transplantation. Based on these promising data, Kiadis Pharma will prepare ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological ...

UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury

... anti-oxidant and an anti-inflammatory drug, following a stroke increases brain cell survival by up to 65 percent. Estrogens delivered intravenously post injury may have similar effects on people with traumatic brain injury. "We know these substances can protect the brain and believe them safe for use ...

Sanofi-aventis Stands Behind the Safety of Lantus(R)

... and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological ...

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

... significance for low-dose bromfenac versus the patients' baseline scores starting as early as Day 14 and sustained through Day 52, ten days post treatment. Lissamine Green, a validated staining technique that stains the entire ocular surface, allows analysis of dry eye damage on the ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... 93% and 96% of patients receiving 200, 300 or 400 mg doses, respectively. There were no clinical relapses at the late follow-up visit 21-28 days post treatment. Highlighting the growing problem of drug resistance in the community, MRSA was the primary pathogen in 72% of the microbiologically ...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

... and Dentistry . "These results indicate that AFRESA may be a promising new therapy for patients with type 1 and type 2 diabetes, as it controls post meal-time glucose levels with the added benefits of less weight gain and lower risk of hypoglycemia." AFRESA is a novel, ultra rapid acting ...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

... treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. About Community Acquired Pneumonia (CAP) CAP is the sixth ...

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

... two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... Three patients had distant metastatic disease. Two of these were in the low dose group. One additional low dose patient developed a new primary tumor post treatment. OncoVEX GM-CSF was detected in injected and adjacent uninjected tumors at a therapeutic dose. Dr Robert Coffin, Founder and ...

Methadone Frequently Causes Menopausal Symptoms in Young Women

... patients, between 20 and 30 years old, who we detoxed from methadone arrived with estradiol, progesterone or testosterone hormone levels, in the post menopausal range." A 1975 University of Pennsylvania study revealed severe hormonal suppression caused by narcotic pain medications. Despite ...

InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients

... the procedure was performed by Dr. Jan Horak. InspireMD plans to enroll 1000 'real world' Mguard(TM) patients. The registry, which is a post market study, will be conducted in Europe, Asia and South America. Data from the registry, an unselected heterogeneous population, will be used to ...

The Villa Group Informs on Mexico Travel Plans in Wake of Swine Flu Outbreak

... 8:00 am - 8:00 pm Eastern Daylight Time, M-F, at 1-888-407-4747, or if calling from outside the U.S., at (202)-501-4444. The U.S. Embassy will also post additional information as it becomes available at: www.usembassy-mexico.gov . About The Villa Group Founded in 1984, The Villa Group has ...

HeartWare International Clinical Trial Shows 90% Survival at 180 Days

... in the trial across 5 participating centers. The data show a survival rate of 90% at 6 months and a survival rate of approximately 86% at 12 months post implant*. On average, the patients were supported by the HeartWare(R) System for 300 days each. The cumulative duration of support across the group ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... Officer. "Although the number of cases of myopathy in the QUASH trials was low and the severity was mild, more severe reports from other trials and post marketing surveillance led us to believe the risk benefit ratio for clevudine was insufficient to continue development. We would like to take this ...

DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium

... at Harbor-UCLA, Torrance, CA; (2)Salem VA Medical Center, Salem, VA; (3)DaVita Inc, El Segundo, CA -- Title: Improved Outcomes post Enrollment in High Touch, Tailored Pharmacy--Meeting the Patients' Need Authors: Maricela Lara-Nevarez(1), Meredith Mathews(1), ...

InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation

... InnoCentive's open innovation web site provides a platform for organizations, companies and government agencies (known as 'Seekers') to post innovation 'Challenges' for the public (known as 'Solvers') to solve for financial reward. NPG and InnoCentive intend to jointly produce an online ...

FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)

... and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological ...

Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production

... of photodynamic therapy used in conjunction with topical therapy to be the first such treatment to achieve complete clearance of acne up to 13 months post treatment and a 77 percent clearance rate per treatment. Four subsequent studies conducted by other investigators involving an additional 75 patients ...

Staying One Step Ahead of Osteoporosis

... an orthopaedic surgeon at Hadassah- Hebrew University Medical Center in Jerusalem, Israel, looked at improving the diagnosis rate of osteoporosis in post menopausal women, who fracture the distal radius bone, which is located in the lower arm, near the wrist. Dr. Kandel says these fractures are often ...